Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Viale

Showing results (11-20 of 527) with videos related to

Pageof 53
Sort By:
Breast (Edinburgh, Scotland)|August 11, 2015
A bad tumor biomarker is as bad as a bad drug: The gap between genomics data and phenotype to predict responseGiuseppe Viale
Breast (Edinburgh, Scotland)|November 17, 2009
Integrating molecular profiling, histological type and other variables: defining the fingerprint of responsiveness to treatmentGiuseppe Viale
Breast (Edinburgh, Scotland)|September 20, 2005
Histopathology of primary breast cancer 2005Giuseppe Viale
Breast (Edinburgh, Scotland)|November 1, 2024
The "lows": Update on ER-low and HER2-low breast cancerNicola Fusco, Giuseppe Viale
Breast (Edinburgh, Scotland)|December 17, 2019
Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched diseaseGiuseppe Viale, Elisabetta Munzone
European Journal of Cancer (Oxford, England : 1990)|September 25, 2009
Pathological definition of triple negative breast cancerGiuseppe Viale, Luca Bottiglieri
Breast (Edinburgh, Scotland)|November 23, 2021
Pathology after neoadjuvant treatment - How to assess residual diseaseGiuseppe Viale, Nicola Fusco
Targeted Oncology|May 3, 2023
HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A PodcastAditya Bardia, Giuseppe Viale
The New England Journal of Medicine|May 24, 2018
The Lymph Node and the MetastasisVivianne Tjan-Heijnen, Giuseppe Viale
Breast (Edinburgh, Scotland)|November 17, 2009
Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant settingMarco Colleoni, Giuseppe Viale, Aron Goldhirsch
Pageof 53

Showing results (11-20 of 527) with videos related to

Sort By:
Pageof 53
Breast (Edinburgh, Scotland)|August 11, 2015
A bad tumor biomarker is as bad as a bad drug: The gap between genomics data and phenotype to predict responseGiuseppe Viale
Breast (Edinburgh, Scotland)|November 17, 2009
Integrating molecular profiling, histological type and other variables: defining the fingerprint of responsiveness to treatmentGiuseppe Viale
Breast (Edinburgh, Scotland)|September 20, 2005
Histopathology of primary breast cancer 2005Giuseppe Viale
Breast (Edinburgh, Scotland)|November 1, 2024
The "lows": Update on ER-low and HER2-low breast cancerNicola Fusco, Giuseppe Viale
Breast (Edinburgh, Scotland)|December 17, 2019
Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched diseaseGiuseppe Viale, Elisabetta Munzone
European Journal of Cancer (Oxford, England : 1990)|September 25, 2009
Pathological definition of triple negative breast cancerGiuseppe Viale, Luca Bottiglieri
Breast (Edinburgh, Scotland)|November 23, 2021
Pathology after neoadjuvant treatment - How to assess residual diseaseGiuseppe Viale, Nicola Fusco
Targeted Oncology|May 3, 2023
HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A PodcastAditya Bardia, Giuseppe Viale
The New England Journal of Medicine|May 24, 2018
The Lymph Node and the MetastasisVivianne Tjan-Heijnen, Giuseppe Viale
Breast (Edinburgh, Scotland)|November 17, 2009
Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant settingMarco Colleoni, Giuseppe Viale, Aron Goldhirsch
Pageof 53